187 related articles for article (PubMed ID: 31971798)
1. Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.
Caravella JA; Lin J; Diebold RB; Campbell AM; Ericsson A; Gustafson G; Wang Z; Castro J; Clarke A; Gotur D; Josephine HR; Katz M; Kershaw M; Yao L; Toms AV; Barr KJ; Dinsmore CJ; Walker D; Ashwell S; Lu W
J Med Chem; 2020 Feb; 63(4):1612-1623. PubMed ID: 31971798
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
Lin J; Lu W; Caravella JA; Campbell AM; Diebold RB; Ericsson A; Fritzen E; Gustafson GR; Lancia DR; Shelekhin T; Wang Z; Castro J; Clarke A; Gotur D; Josephine HR; Katz M; Diep H; Kershaw M; Yao L; Kauffman G; Hubbs SE; Luke GP; Toms AV; Wang L; Bair KW; Barr KJ; Dinsmore C; Walker D; Ashwell S
J Med Chem; 2019 Jul; 62(14):6575-6596. PubMed ID: 31199148
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Optimization of 2
Rohde JM; Karavadhi S; Pragani R; Liu L; Fang Y; Zhang W; McIver A; Zheng H; Liu Q; Davis MI; Urban DJ; Lee TD; Cheff DM; Hollingshead M; Henderson MJ; Martinez NJ; Brimacombe KR; Yasgar A; Zhao W; Klumpp-Thomas C; Michael S; Covey J; Moore WJ; Stott GM; Li Z; Simeonov A; Jadhav A; Frye S; Hall MD; Shen M; Wang X; Patnaik S; Boxer MB
J Med Chem; 2021 Apr; 64(8):4913-4946. PubMed ID: 33822623
[TBL] [Abstract][Full Text] [Related]
5. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J
Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
Ma T; Zou F; Pusch S; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
Bioorg Med Chem; 2017 Dec; 25(24):6379-6387. PubMed ID: 29089260
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
Ma T; Zou F; Pusch S; Xu Y; von Deimling A; Zha X
J Med Chem; 2018 Oct; 61(20):8981-9003. PubMed ID: 29847930
[TBL] [Abstract][Full Text] [Related]
8. Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction.
Zhou X; Zheng M; Zhao N; Hu Y; Yang K; Huo J; Liu G; Huang J; Chen L; Zhou Y; Li H
Bioorg Chem; 2022 Feb; 119():105569. PubMed ID: 34954572
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.
Zou F; Pusch S; Hua J; Ma T; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
Bioorg Med Chem Lett; 2018 Feb; 28(3):388-393. PubMed ID: 29290542
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Liu Z; Yao Y; Kogiso M; Zheng B; Deng L; Qiu JJ; Dong S; Lv H; Gallo JM; Li XN; Song Y
J Med Chem; 2014 Oct; 57(20):8307-18. PubMed ID: 25271760
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-
Wu Y; Wang B; Wang J; Qi S; Zou F; Qi Z; Liu F; Liu Q; Chen C; Hu C; Hu Z; Wang A; Wang L; Wang W; Ren T; Cai Y; Bai M; Liu Q; Liu J
J Med Chem; 2019 Jul; 62(13):6083-6101. PubMed ID: 31250638
[TBL] [Abstract][Full Text] [Related]
12. Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
Zheng Q; Tang S; Fu X; Chen Z; Ye Y; Lan X; Jiang L; Huang Y; Ding J; Geng M; Huang M; Wan H
Bioorg Med Chem Lett; 2017 Dec; 27(23):5262-5266. PubMed ID: 29079473
[TBL] [Abstract][Full Text] [Related]
13. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
de la Fuente MI; Colman H; Rosenthal M; Van Tine BA; Levacic D; Walbert T; Gan HK; Vieito M; Milhem MM; Lipford K; Forsyth S; Guichard SM; Mikhailov Y; Sedkov A; Brevard J; Kelly PF; Mohamed H; Monga V
Neuro Oncol; 2023 Jan; 25(1):146-156. PubMed ID: 35639513
[TBL] [Abstract][Full Text] [Related]
14. Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
Zheng Q; Chen Z; Wan H; Tang S; Ye Y; Xu Y; Jiang L; Ding J; Geng M; Huang M; Huang Y
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3808-3812. PubMed ID: 30413349
[TBL] [Abstract][Full Text] [Related]
15. I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo.
Jia P; Wu Y; Du H; Yang L; Zhang Z; Ma T; Li S; Yuan S; Lu L; Zha X
Eur J Pharm Sci; 2019 Dec; 140():105072. PubMed ID: 31518680
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of new quinoline derivatives as potential antitumor agents.
Su T; Zhu J; Sun R; Zhang H; Huang Q; Zhang X; Du R; Qiu L; Cao R
Eur J Med Chem; 2019 Sep; 178():154-167. PubMed ID: 31181480
[TBL] [Abstract][Full Text] [Related]
17. Clinical development of IDH1 inhibitors for cancer therapy.
Zarei M; Hue JJ; Hajihassani O; Graor HJ; Katayama ES; Loftus AW; Bajor D; Rothermel LD; Vaziri-Gohar A; Winter JM
Cancer Treat Rev; 2022 Feb; 103():102334. PubMed ID: 34974243
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors.
Liu X; Hu Y; Gao A; Xu M; Gao L; Xu L; Zhou Y; Gao J; Ye Q; Li J
Bioorg Med Chem; 2019 Feb; 27(4):589-603. PubMed ID: 30600148
[TBL] [Abstract][Full Text] [Related]
19. Olutasidenib: from bench to bedside.
Venugopal S; Watts J
Blood Adv; 2023 Aug; 7(16):4358-4365. PubMed ID: 37196640
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Potent Small-Molecule SIRT6 Activators: Structure-Activity Relationship and Anti-Pancreatic Ductal Adenocarcinoma Activity.
Chen X; Sun W; Huang S; Zhang H; Lin G; Li H; Qiao J; Li L; Yang S
J Med Chem; 2020 Sep; 63(18):10474-10495. PubMed ID: 32787077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
